CSL Limited (OTCMKTS:CSLLY) Sees Large Growth in Short Interest

CSL Limited (OTCMKTS:CSLLY) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 11,800 shares, an increase of 151.1% from the December 31st total of 4,700 shares. Based on an average daily volume of 159,800 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a report on Thursday, January 16th.

CSL Price Performance

CSLLY traded up $0.07 on Wednesday, reaching $85.23. The company had a trading volume of 144,418 shares, compared to its average volume of 69,933. CSL has a one year low of $83.31 and a one year high of $109.00. The company has a fifty day moving average of $88.30 and a 200-day moving average of $95.65. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.